AIDS and AIDS-treatment neuropathies

Area of Science:

• Neurology
• Infectious Diseases
• Pharmacology

Background:

• HIV/AIDS and associated treatments can cause painful neuropathies.
• Improved antiretroviral therapies lead to longer patient survival, increasing the impact of neuropathy.
• Antiretroviral medications, while beneficial for viral suppression, can induce toxic neuropathies.

Purpose of the Study:

• To summarize current understanding of AIDS and AIDS-treatment neuropathies.
• To explore the pathogenesis of these neuropathies.
• To review treatment strategies for painful neuropathy in HIV/AIDS patients.

Main Methods:

• Literature review of existing studies on HIV-associated neuropathies.
• Analysis of current theories regarding the mechanisms of neuropathy development.
• Evaluation of treatment approaches, including symptomatic relief and antiretroviral therapy.

Main Results:

• Mitochondrial toxicity, stemming from gamma-DNA polymerase inhibition and impaired mitochondrial DNA synthesis, is a leading theory for pathogenesis.
• Symptomatic treatment is the current standard for AIDS neuropathies.
• Emerging evidence indicates aggressive antiretroviral therapy may also be an effective treatment.

Conclusions:

• AIDS and its treatments frequently cause neuropathies, impacting quality of life for long-term survivors.
• Understanding the pathogenesis, including mitochondrial dysfunction, is crucial.
• Aggressive antiretroviral therapy presents a promising avenue for managing AIDS-related neuropathies, potentially offering benefits beyond viral suppression.